Postcovid cognitive impairment

Shishkova V.N.; Dranitsina B.G.

doi:https://doi.org/10.17116/jnevro202212212145

Close metadata

Recommended articles:

Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16

Comparative study of cognitive impairment in subgroups of bipolar affective disorder types I and II, occurring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11

Relationship between stroke-associated pneumonia and long-term outcomes of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):57-61

Modern approaches to diagnosis and treatment of postinfectious asthenic syndrome in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):42-52

Potential of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):83-87

Incidence of diseases of the circulatory system in the working-age population of the Ural Federal District in 2012—2022. Russian Journal of Preventive Medicine. 2025;(1):24-29

Post-COVID syndrome: organizing COVID-19-associated pneumonia. Clinical case. Journal of Respiratory Medicine. 2025;(1):65-72

Rehabilitation of patients with post-COVID syndrome depending on C(159)T polymorphism of SD-14 gene. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(1):42-50

Study of the levocarnitine efficacy for the treatment of moderate cognitive impairment in patients with hypertension. Russian Journal of Preventive Medicine. 2025;(4):45-50

Impact of the COVID-19 epidemic on students’ health. Part II. Features of hemodynamics, vegetative regulation, results of psychological and stress resistance testing among students depending on the COVID-19 presence in their medical history. Russian Journal of Preventive Medicine. 2025;(4):94-101

Abstract:

This review addresses current issues in post-COVID syndrome with a focus on neurocognitive impairment. The results of studies on complications in patients of different ages and health statuses recovered from mild to severe COVID-19 are discussed. Current data on the pathogenetic mechanisms of the development of various post-COVID disorders are presented, including a detailed discussion of central nervous system damage. The paper summarizes data on the relationship between neurocognitive disorders and accelerated cell aging, chronic nonspecific inflammation, and reduced neuroplasticity in the central nervous system. The main pathogenetic ways to prevent COVID-related complications, including neuronal tissue damage and the prospects for managing such patients are discussed. The choice of pathogenetic therapy in patients with neurocognitive impairment in the post-COVID period is assessed. The main benefits of choline alfoscerate therapy for neurocognitive impairment in patients with post-COVID syndrome are discussed.

Keywords:

new coronavirus infection

neurocognitive impairment

post-COVID syndrome

choline alfoscerate

Cereton

Rakona

Authors:

Shishkova V.N.

National Medical Research Center for Therapy and Preventive Medicine Federal State Budgetary Institution the Ministry of Health of Russia;
A.I. Yevdokimov Moscow State University of Medicine and Dentistry Federal State Budgetary Educational Institution of Higher Education

SPIN RSCI: 8507-5980
Scopus AuthorID: 25932318700
ResearcherID: AAJ-2413-2021
ORCID: 0000-0002-1042-4275

Dranitsina B.G.

National Medical Research Center for Therapy and Preventive Medicine

Received:

09.11.2022

Accepted:

10.11.2022

Close metadata

References:

Prevention, diagnosis and treatment of new coronavirus infection (COVID-19): Version 15 of 02/22/2022. Avdeev S.N., Adamyan L.V., Alekseeva E.I., et al. M.: Ministry of Health of the Russian Federation; 2022;245. (In Russ.)
World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Accessed 2021 Dec 21. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.
Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of Long-COVID. Nat Med. 2021;27(4):626-631. https://doi.org/10.1038/s41591-021-01292-y
Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-232. https://doi.org/10.1016/S0140-6736(20)32656-8
Salmon-Ceron D, Slama D, De Broucker T, et al. APHP COVID-19 research collaboration. Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: a cross-sectional study. J Infect. 2021;82(2):e1-4. https://doi.org/10.1016/j.jinf.2020.12.002
Alemanno F, Houdayer E, Parma A, et al. COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID-rehabilitation unit experience. PLoS ONE. 2021;16(2):e0246590. https://doi.org/10.1371/journal.pone.0246590
Nersesjan V, Fonsmark L, Christensen RHB, et al. Neuropsychiatric and Cognitive Outcomes in Patients 6 Months After COVID-19 Requiring Hospitalization Compared With Matched Control Patients Hospitalized for Non-COVID-19 Illness. JAMA Psychiatry. 2022;79(5):486-497. https://doi.org/10.1001/jamapsychiatry.2022.0284
Hellmuth J, Barnett TA, Asken BM, et al. Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. J Neurovirol. 2021;27(1):191-195. https://doi.org/10.1007/s13365-021-00954-4
Abdelghani M, Atwa SA, Said A, et al. Cognitive after-effects and associated correlates among post-illness COVID-19 survivors: a cross-sectional study, Egypt. Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):77-81. https://doi.org/10.1186/s41983-022-00505-6
Hampshire A, Trender W, Chamberlain SR, et al. Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine. 2021;39:101044. https://doi.org/10.1016/j.eclinm.2021.101044
Oronsky B, Larson C, Hammond TC, et al. A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. 2021;20(8):1-9. https://doi.org/10.1007/s12016-021-08848-3
Alonso-Lana S, Marquié M, Ruiz A, Boada M. Cognitive and neuropsychiatric manifestations of COVID-19 and effects on elderly individuals with dementia. Front Aging Neurosci. 2020;12(5):588872. https://doi.org/10.3389/fnagi.2020.588872
Heneka MT, Golenbock D, Latz E, et al. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020;12(1):69-73.
Ogier M, Andéol G, Sagui E, Dal Bo G. How to detect and track chronic neurologic sequelae of COVID-19? Use of auditory brainstem responses and neuroimaging for long-term patient follow-up. Brain Behav Immun Health. 2020;5(4):100081. https://doi.org/10.1016/j.bbih.2020.100081
Coolen T, Lolli V, Sadeghi N, et al. Early postmortem brain MRI findings in COVID-19 non-survivors. Neurology. 2020;95(14):e2016-27. https://doi.org/10.1212/WNL.0000000000010116
Reichard RR, Kashani KB, Boire NA, et al. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol. 2020;140(1):1-6. https://doi.org/10.1007/s00401-020-02166-2
Netland J, Meyerholz DK, Moore S, et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82(15):7264-7275. https://doi.org/10.1128/JVI.00737-08
Dantzer R. Neuroimmune interactions: from the brain to the immune system and vice versa. Physiol Rev. 2018;98(1):477-504. https://doi.org/10.1152/physrev.00039.2016
Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418. https://doi.org/10.1016/S0140-6736(20)30937-5
Zhou Z, Kang H, Li S, Zhao X. Understanding the neurotropic characteristics of SARSCoV-2: From neurological manifestations of COVID-19 to potential neurotropic mechanisms. J Neurol. 2021;267(8):2179-2284. https://doi.org/10.1007/s00415-020-09929-7
Ehrenfeld M, Tincani A, Andreoli L, et al. COVID-19 and autoimmunity. Autoimmun Rev. 2020;19(8):102597. https://doi.org/10.1016/j.autrev.2020.102597
Bektas A, Schurman SH, Franceschi C, Ferrucci L. A public health perspective of aging: Do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging? Immun Ageing. 2020;17(7):23-30. https://doi.org/10.1186/s12979-020-00196-8
Tremblay ME, Madore C, Bordeleau M, et al. Neuropathobiology of COVID-19: The Role for Glia. Front Cell Neurosci. 2020;14(6):592214. https://doi.org/10.3389/fncel.2020.592214
Gennaro MM, Mariagrazia P, De Lorenzo R, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun. 2021;94:138-147. https://doi.org/10.1016/j.bbi.2021.02.021
Alpert O, Begun L, Garren P, Solhkhah R. Cytokine storm induced new onset depression in patients with COVID-19. A new look into the association between depression and cytokines — two case reports. Brain Behav Immun Health. 2020;9(6);100173. https://doi.org/10.1016/j.bbih.2020.100173
Ortelli P, Ferrazzoli D, Sebastianelli L, et al. Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: Insights into a challenging symptom. J Neurol Sci. 2021;420:117271. https://doi.org/10.1016/j.jns.2020.117271
Sadigh-Eteghad S, Mahmoudi J, Babri S, Talebi M. Effect of alpha-7 nicotinic acetylcholine receptor activation on beta-amyloid induced recognition memory impairment. Possible role of neurovascular function. Acta Cir Bras. 2015;30(5):736-742. https://doi.org/10.1590/S0102-865020150110000003
Humphreys H, Kilby L, Kudiersky N, Copeland R. Long COVID and the role of physical activity: a qualitative study. BMJ Open. 2021;11(3):e047632. https://doi.org/10.1136/bmjopen-2020-047632
Vertkin AL, Shishkova VN, Sycheva AS, et al. Possibilities of metabolic support in coronavirus infection. Therapy. 2020;7(41):146-155. (In Russ.). https://doi.org/10.18565/therapy.2020.7.146-155
Shishkova VN, Martynov AI. New possibilities in the treatment of asthenic symptoms after a new coronavirus infection. Medical Council. 2022;16(6):24-35. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-6-24-35
Dąbrowska E, Galińska-Skok B, Waszkiewicz N. Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19. Life (Basel). 2021;11(10):1056. https://doi.org/10.3390/life11101056
Shishkova VN, Imamgayazova KE, Kapustina LA. Correction of psychoemotional disorders and short-term prognosis in patients with COVID-19. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(5):63-68. (In Russ.). https://doi.org/10.17116/jnevro202212205163
Roy P, Tomassoni D, Nittari G, et al. Effects of choline containing phospholipids on the neurovascular unit: A review. Front Cell Neurosci. 2022;16(4):988759. https://doi.org/10.3389/fncel.2022.988759
Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha glyceryl-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent. Curr Alzheimer Res Dec. 2013;10(8):1070-1079. https://doi.org/10.2174/15672050113106660173
Tomassoni D, Avola R, Mignini F, et al. Effect of treatment with choline alphoscerate on hippocampus microanatomy and glial reaction in spontaneously hypertensive rats. Brain Res. 2006;11(20):183-190. https://doi.org/10.1016/j.brainres.2006.08.068
Shishkova VN, Malyukova NG, Tokareva RB. Studying the effectiveness of the drug cereton in complex neurorehabilitation therapy. Medical Business. 2020;1(9):55-62. (In Russ.). https://doi.org/10.24411/2071-5315-2020-12193
Kamchatnov PR, Abusueva BA, Evzelman MA, et al. The effectiveness of cereton in acute ischemic stroke (results of the SUN study). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;3(2):10-14. (In Russ.).
Buivolova TV, Glotova ME, Halak ME, Vashkevich VV. The experience of using cereton in the rehabilitation of patients with hemorrhagic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2009;5(2):58-62. (In Russ.).
Gavrilova SI, Kolykhalov IV, Ponomareva EV, et al. Clinical efficacy and safety of choline alfoscerate in the treatment of late-onset cognitive impairment. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(5):45-53. (In Russ.). https://doi.org/10.17116/jnevro20181185145
https://doi.org/10.24411/2226-0757-2020-12183 https://doi.org/10.24411/2226-0757-2020-12183